Simone M. Goldinger

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text

Medicine, Cancer Biology, Oncology +17

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

David Liu, Bastian Schilling, Derek Liu et al. · Nature Medicine · 2019 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Eliezer M. Van Allen, Nikhil Wagle, Antje Sucker et al. · Cancer Discovery · 2013 · 940 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann, Andrea Forschner, Carmen Loquai et al. · European Journal of Cancer · 2016 · 647 citations

Pharmacy, Pharmacology, Pharmacotherapy +14